ArticleAntimicrobial resistance and infection control2026
The missing link in combating antimicrobial resistance: leveraging vaccines for prevention.
Article in Antimicrobial resistance and infection control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Antimicrobial resistance (AMR) threatens to claim 10 million lives annually by 2050, yet vaccines-proven tools to prevent infections and reduce antibiotic use-remain underutilized in AMR strategies. Despite evidence that pediatric vaccination could prevent 181,500 AMR-associated deaths annually in low- and middle-income countries (LMICs) and that pneumococcal conjugate vaccines reduce nonsusceptible infections by 56.9%, vaccines are rarely integrated into National AMR Action Plans with explicit targets, financing mechanisms, or surveillance linkages. AMR and immunization programs operate as separate vertical structures with different champions, financing streams, and data systems. This siloed approach prevents operationalization of vaccine-AMR evidence into policy and limits coordinated action. National AMR Action Plans prioritize stewardship, surveillance, and drug discovery while overlooking vaccines' role in reducing infection burden, limiting resistant pathogen circulation, and decreasing antibiotic consumption. This commentary argues that vaccines must be treated as core AMR infrastructure in LMICs, requiring five governance shifts: (1) institutionalized collaboration between immunization and AMR stakeholders; (2) vaccine coverage targets embedded in AMR action plans; (3) coordinated surveillance linking immunization registries with AMR data systems; (4) financing mechanisms recognizing vaccines as AMR infrastructure investments; and (5) research prioritizing next-generation vaccines against resistant pathogens. Drawing on efforts in the Philippines to convene physician societies, government agencies leading AMR and immunization efforts, and academic institutions, we demonstrate how these shifts can be piloted through a formal AMR-Vaccine Network, offering a testable model for operationalizing vaccine-AMR integration in LMICs. The challenge extends beyond establishing the evidence base to operationalizing that evidence through governance reform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.